5-氟尿嘧啶与低剂量重组干扰素α-2a治疗激素难治性前列腺腺癌患者

5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.

作者信息

Shinohara N, Demura T, Matsumura K, Toyoda K, Kashiwagi A, Nagamori S, Ohmuro H, Ohzono S, Koyanagi T

机构信息

Department of Urology, Hokkaido University School of Medicine, Japan.

出版信息

Prostate. 1998 Apr 1;35(1):56-62. doi: 10.1002/(sici)1097-0045(19980401)35:1<56::aid-pros8>3.0.co;2-f.

DOI:10.1002/(sici)1097-0045(19980401)35:1<56::aid-pros8>3.0.co;2-f

PMID:9537600

Abstract

BACKGROUND

The effectiveness of a chemotherapy regimen including 5-fluorouracil (5-FU) and recombinant interferon-alpha-2a (rIFN-alpha-2a) was evaluated in hormone-refractory prostate cancer patients.

METHODS

Patients received a continuous intravenous infusion of 5-FU at 600 mg/m2/day for 5 days (D1-D5), followed by a bolus injection of 5-FU on D15 and D22. Patients received intramuscular injection of rIFN-alpha-2a at 3 million IU on D1, D3, D5, D15, and D22. This schedule was repeated every 4 weeks.

RESULTS

Between 1993 and 1995, 23 patients with hormone refractory prostate cancer were enrolled in this study. Two of five patients with nodal disease exhibited partial responses according to the NPCP criteria. Fourteen of 17 patients with bone disease showed stable disease. Of 21 patients assessible for response, 9 patients had a decrease in the PSA level greater than 50% of baseline. Bone pain disappeared partially or completely in 8 of 14 patients with this symptom at entry. The median overall survival was 18 months. The associate toxicity was well tolerable.

CONCLUSIONS

Combination chemotherapy of 5-FU and low dose rIFN-alpha-2a in patients with hormone-refractory prostate cancer proved feasible, and with acceptable toxicity.

摘要

背景

对激素难治性前列腺癌患者评估了一种包含5-氟尿嘧啶（5-FU）和重组干扰素α-2a（rIFN-α-2a）的化疗方案的有效性。

方法

患者接受5-氟尿嘧啶以600mg/m²/天的剂量持续静脉输注5天（第1 - 5天），随后在第15天和第22天进行5-氟尿嘧啶推注。患者在第1、3、5、15和22天接受300万国际单位的rIFN-α-2a肌肉注射。该方案每4周重复一次。

结果

1993年至1995年期间，23例激素难治性前列腺癌患者纳入本研究。根据NPCP标准，5例有淋巴结转移的患者中有2例出现部分缓解。17例有骨转移的患者中有14例病情稳定。在可评估缓解情况的21例患者中，9例患者的前列腺特异性抗原（PSA）水平下降超过基线的50%。14例初诊时有骨痛症状的患者中，8例患者的骨痛部分或完全消失。中位总生存期为18个月。相关毒性耐受性良好。